Source: Eur Respir Rev, 26 (145) 170053; 10.1183/16000617.0053-2017
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Sebastiano Emanuele Torrisi, Mauro Pavone, Ada Vancheri, Carlo Vancheri. When to start and when to stop antifibrotic therapies. Eur Respir Rev, 26 (145) 170053; 10.1183/16000617.0053-2017

Member's Comments

No comment yet.

Related content which might interest you: Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 How to stop LC-fILD progression: an overview of modern therapeutic strategies Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Timely start of HFNC treatment is beneficial for the outcome in COVID-19 Source: Virtual Congress 2021 – Non-invasive respiratory support in COVID-19 Year: 2021 Alternative immunosuppressive strategies Source: ERS Course 2016 Year: 2016 GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004 Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021 Year: 2021 Targeting targeted therapies: more choices and the best sequences Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 Do we have any alternative therapeutic option beyond antibiotics? Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions Year: 2021 Old and new strategies in induction therapy Source: School Course 2012 - Lung Transplantation Year: 2012 Next generation of anti-inflammatory therapy for COPD? Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017 Year: 2017 How to manage side-effects of targeted therapies? Source: Annual Congress 2010 - PG7 Postgraduate Course: How to manage treatment complications of lung cancer Year: 2010 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Impact of antifibrotic drugs in lung transplantation Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes Year: 2019 What influences patient choice of antifibrotic treatment in IPF? Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world Year: 2020